IRLAB Therapeutics - New mesdopetam patent strengthens IP portfolio
IRLAB Therapeutics has been granted a new patent in Europe for its lead asset, Phase-III ready mesdopetam, which potentially extends its market exclusivity beyond the previous 2037 expiry. The updated patent relates to a new salt of the drug (which has been used during the ongoing clinical development) and the process for its preparation, extending protection to 2040. Mesdopetam is IRLAB’s most advanced asset, targeting levodopa-induced dyskinesias in Parkinson’s disease (PD-LIDs), a debilitating condition inflicting over 30% of the PD patient population. Following IRLAB’s successful end-of-Phase II (EoP2) meeting with the FDA, we believe that Phase III trials could start as early as Q424 or Q125, depending on partnership discussions. We view this as the most significant upcoming catalyst for the company.IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson's disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson's Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.